Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MariMedMRMD +1.06% Forward PE Ratio is 7.03 as of Jul. 20, 2026. The stock has 5 warning signs investors should review. Among 409 Drug Manufacturers companies, MariMed ranks better than 91.2% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
MariMed Forward PE Ratio Related Terms
MariMed Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for MariMed's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MariMed Forward PE Ratio Chart
MariMed Annual Data
Trend
2022-12
Forward PE Ratio
19.01
MariMed Quarterly Data
2022-09
2022-12
2023-03
2023-09
Forward PE Ratio
8.87
19.01
44.84
21.74
MRMD vs RMTI, CPHI, TXMD: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MariMed Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MariMed's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where MariMed's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
MariMed (MRMD) has a Forward PE Ratio of 7.03 as of Jul. 20, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on MariMed and its competitors. According to the industry distribution chart, MariMed ranks #36 out of 409 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is MariMed's Forward PE Ratio too high?
MariMed's current Forward PE Ratio is 7.03. The Drug Manufacturers industry median Forward PE Ratio is 17.21. MariMed's value of 7.03 is 59.2% below this industry median. Based on the distribution chart, MariMed ranks #36 out of 409 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does MariMed's Forward PE Ratio compare to RMTI and CPHI?
According to the Drug Manufacturers industry distribution chart, MariMed ranks #36 out of 409 companies for Forward PE Ratio. This places MariMed in the top 9% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 17.21. MariMed's value of 7.03 is 59.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.21, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MariMed's current Forward PE Ratio of 7.03 is 59.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on MariMed and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MariMed's current Forward PE Ratio is 7.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.16, compared to a current price of $0.07 — trading 58.4% below its estimated fair value. The current Forward PE Ratio is 7.03 and 59.2% below the Drug Manufacturers industry median of 17.21. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For MariMed (MRMD), the current Forward PE Ratio is 7.03 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRMD has been successfully added to your 
